EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

OATP1B1/1B3 deficiency exacerbates hyperbilirubinemia in erythropoietic protoporphyria

Ruizhi Gu, Fu-Ying Qin, Luxuan Wang, Jiaojiao Zhang, Jacob Emerson, Qing Ma, Jie Lu, Karl E Anderson, Junmei Wang, Xiaochao Ma

Drug Metabolism and Disposition · 2025

DOI: 10.1016/j.dmd.2025.100105 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Metabolism and Disposition, 2025. Verfasst von Ruizhi Gu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Center for Pharmacogenetics, Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, Pennsylvania. Hauptthemen laut MEDLINE: Liver-Specific Organic Anion Transporter 1, Protoporphyria, Erythropoietic, Hyperbilirubinemia, Solute Carrier Organic Anion Transporter Family Member 1B3. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, National Institute of Diabetes and Digestive and Kidney Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Erythropoietic protoporphyria (EPP) is caused by loss-of-function mutations in ferrochelatase (FECH), leading to the accumulation of its substrate, protoporphyrin IX (PPIX). PPIX is primarily produced in the bone marrow and transported to the liver for excretion. Because PPIX is hydrophobic, its elevated levels can cause bile duct blockage, cholestatic liver injury, and even liver failure. However, the specific transporter responsible for PPIX uptake into hepatocytes remains unclear. The OATP1B1/1B3 transporters, which are expressed in hepatocytes, facilitate the uptake of coproporphyrin III, a structural analog of PPIX. Additionally, OATP1B1/1B3 mediates the uptake of bilirubin, a biomarker of liver injury, from plasma into the liver for excretion. Therefore, we aimed to determine the role of OATP1B1/1B3 in regulating PPIX and bilirubin homeostasis under EPP conditions. A mouse strain carrying a Fech mutation was used as an EPP model. Building on this, we generated a new EPP mouse model with Oatp1a/1b deficiency. Using these EPP mouse models, along with OATP1B1/1B3-overexpressing cells, our study revealed that PPIX is not a substrate of OATP1B1/1B3. Notably, our work found that genetic deficiency or pharmacologic suppression of Oatp1a/1b exacerbates hyperbilirubinemia in EPP mice without worsening liver injury. Mechanistically, Oatp1a/1b deficiency impairs bilirubin uptake from plasma, while Fech deficiency leads to PPIX-mediated bile duct blockage and reduced bilirubin excretion, synergistically exacerbating hyperbilirubinemia. In summary, our work demonstrated that deficiency or suppression of Oatp1a/1b exacerbates hyperbilirubinemia in EPP mouse models, suggesting that assessment of OATP1B1/1B3 function is crucial in EPP patients with EPP with hyperbilirubinemia. SIGNIFICANCE STATEMENT: This work revealed that serum bilirubin levels are not paralleled with liver damage in the erythropoietic protoporphyria mouse models with Oatp1a/1b deficiency. Our findings suggest that assessment of OATP1B1/1B3 function is crucial in patients with erythropoietic protoporphyria with hyperbilirubinemia.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver-Specific Organic Anion Transporter 1Protoporphyria, ErythropoieticHyperbilirubinemiaSolute Carrier Organic Anion Transporter Family Member 1B3AnimalsMiceBilirubinProtoporphyrinsHepatocytesHumansMice, KnockoutCoproporphyrinsMaleLiverMice, Inbred C57BLDisease Models, Animal

Stichwörter der Autor:innen

BilirubinLiver diseasesOATPsProtoporphyrin IX

Substanzen

Liver-Specific Organic Anion Transporter 1BilirubinSolute Carrier Organic Anion Transporter Family Member 1B3Protoporphyrinsprotoporphyrin IXCoproporphyrins

Autor:innen und Institutionen

  • Center for Pharmacogenetics, Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, Pennsylvania.
  • Computational Chemical Genomics Screening Center, Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, Pennsylvania.
  • Department of Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, New York.
  • Porphyria Laboratory & Center, Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Texas Medical Branch, Galveston, Texas.
  • Center for Pharmacogenetics, Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, Pennsylvania. Electronic address: mxiaocha@pitt.edu.

Förderung

  • NIDDK NIH HHS
  • National Institute of Diabetes and Digestive and Kidney Diseases

Zitieren

APA

Gu, R., Qin, F. Y., Wang, L., Zhang, J., Emerson, J., Ma, Q., Lu, J., Anderson, K. E., Wang, J., & Ma, X. (2025). OATP1B1/1B3 deficiency exacerbates hyperbilirubinemia in erythropoietic protoporphyria. Drug Metabolism and Disposition. https://doi.org/10.1016/j.dmd.2025.100105

Vancouver

Gu R, Qin FY, Wang L, Zhang J, Emerson J, Ma Q, et al. OATP1B1/1B3 deficiency exacerbates hyperbilirubinemia in erythropoietic protoporphyria. Drug Metabolism and Disposition. 2025. doi:10.1016/j.dmd.2025.100105

BibTeX
@article{Gu2025,
  author = {Gu, Ruizhi and Qin, Fu-Ying and Wang, Luxuan and Zhang, Jiaojiao and Emerson, Jacob and Ma, Qing and Lu, Jie and Anderson, Karl E and Wang, Junmei and Ma, Xiaochao},
  title = {OATP1B1/1B3 deficiency exacerbates hyperbilirubinemia in erythropoietic protoporphyria},
  journal = {Drug Metabolism and Disposition},
  year = {2025},
  doi = {10.1016/j.dmd.2025.100105}
}
Kostenlos starten →